202 related articles for article (PubMed ID: 32840904)
1. Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.
Jatt LP; Gandhi MM; Guo R; Sukhija-Cohen A; Bhattacharya D; Tseng CH; Chew KW
J Gastroenterol Hepatol; 2021 Apr; 36(4):1095-1102. PubMed ID: 32840904
[TBL] [Abstract][Full Text] [Related]
2. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.
Socías ME; Ti L; Dong H; Shoveller J; Kerr T; Montaner J; Milloy MJ
HIV Med; 2017 Oct; 18(9):647-654. PubMed ID: 28294492
[TBL] [Abstract][Full Text] [Related]
4. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.
Chen PH; Yenokyan K; Fojo AT; Hutton HE; Lesko CR; McCaul ME; Yang C; Cachay ER; Crane HM; Jacobson JM; Kim HN; Kitahata MM; Mayer KH; Moore RD; Napravnik S; Saag M; Lau B; Chander G
Drug Alcohol Depend; 2022 Dec; 241():109673. PubMed ID: 36332596
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Amele S; Peters L; Rodger A; Lundgren J; Rockstroh J; Matulionyte R; Leen C; Jabłonowska E; Østergaard L; Bhagani S; Sarcletti M; Clarke A; Falconer K; Wandeler G; Domingo P; Maltez F; Zaccarelli M; Chkhartisvili N; Szlavik J; Stephan C; Fonquernie L; Aho I; Mocroft A;
J Acquir Immune Defic Syndr; 2021 Feb; 86(2):248-257. PubMed ID: 33079903
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
[TBL] [Abstract][Full Text] [Related]
8. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection.
van Boemmel-Wegmann S; Lo Re V; Park H
Dig Dis Sci; 2020 Nov; 65(11):3159-3174. PubMed ID: 31938995
[TBL] [Abstract][Full Text] [Related]
9. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment.
Ryscavage P; Hussien S; Seung H; Hynicka L
HIV Med; 2024 May; 25(5):622-627. PubMed ID: 38273652
[TBL] [Abstract][Full Text] [Related]
11. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
Taylor LE; Swan T; Matthews GV
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
[TBL] [Abstract][Full Text] [Related]
12. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.
Peters L; Laut K; Resnati C; Del Campo S; Leen C; Falconer K; Trofimova T; Paduta D; Gatell J; Rauch A; Lacombe K; Domingo P; Chkhartishvili N; Zangerle R; Matulionyte R; Mitsura V; Benfield T; Zilmer K; Khromova I; Lundgren J; Rockstroh J; Mocroft A;
AIDS; 2018 Sep; 32(14):1995-2004. PubMed ID: 29912062
[TBL] [Abstract][Full Text] [Related]
13. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
15. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
16. High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands.
Boerekamps A; Newsum AM; Smit C; Arends JE; Richter C; Reiss P; Rijnders BJA; Brinkman K; van der Valk M;
Clin Infect Dis; 2018 Apr; 66(9):1352-1359. PubMed ID: 29186365
[TBL] [Abstract][Full Text] [Related]
17. Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination.
Du P; Jung J; Kalidindi Y; Farrow K; Riley T; Whitener C
J Public Health Manag Pract; 2022 Mar-Apr 01; 28(2):130-134. PubMed ID: 32011599
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.
Manzardo C; Londoño MC; Castells L; Testillano M; Luis Montero J; Peñafiel J; Subirana M; Moreno A; Aguilera V; Luisa González-Diéguez M; Calvo-Pulido J; Xiol X; Salcedo M; Cuervas-Mons V; Manuel Sousa J; Suarez F; Serrano T; Ignacio Herrero J; Jiménez M; Fernandez JR; Giménez C; Del Campo S; Esteban-Mur JI; Crespo G; Moreno A; de la Rosa G; Rimola A; Miro JM;
Am J Transplant; 2018 Oct; 18(10):2513-2522. PubMed ID: 29963780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
